Claims for Patent: 9,314,462

Summary for Patent: 9,314,462

Title:	Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Abstract:	This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US14/878,998
Patent Claims:	1. A method of increasing dextromethorphan plasma levels in the human being that is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, comprising co-administering hydroxybupropion or bupropion with dextromethorphan to a human being once or twice a day for at least eight consecutive days, wherein the daily dose of dextromethorphan is about 40 mg to about 600 mg, and co-administering hydroxybupropion or bupropion with dextromethorphan results in an AUC0-12 of dextromethorphan that, on the eighth day, is at least about 20 times the AUC0-12 that would be achieved by administering the same amount of dextromethorphan without hydroxybupropion or bupropion for eight consecutive days. 2. The method of claim 1, wherein the daily dose of dextromethorphan is about 60 mg to about 260 mg. 3. The method of claim 1, wherein the daily dose of dextromethorphan is about 60 mg to about 120 mg. 4. The method of claim 1, wherein the daily dose of dextromethorphan is about 60 mg to about 100 mg. 5. The method of claim 1, wherein the dextromethorphan is co-administered in a dosage form that contains about 40 mg to about 50 mg of dextromethorphan. 6. The method of claim 4, wherein the dextromethorphan is co-administered in a dosage form that contains about 40 mg to about 50 mg of dextromethorphan. 7. The method of claim 1, wherein the hydroxybupropion or bupropion and dextromethorphan are co-administered together in a single solid oral dosage form. 8. The method of claim 7, wherein the single solid oral dosage form further comprises a binder, a disintegrating agent, or a lubricant. 9. The method of claim 1, further comprising co-administering hydroxybupropion or bupropion with dextromethorphan to the human being once or twice a day for at least 30 consecutive days. 10. The method of claim 1, further comprising co-administering hydroxybupropion or bupropion with dextromethorphan to the human being once or twice a day for at least 60 consecutive days. 11. The method of claim 1, further comprising co-administering hydroxybupropion or bupropion with dextromethorphan to the human being once or twice a day for at least 180 consecutive days. 12. The method of claim 1, comprising co-administering hydroxybupropion or bupropion with dextromethorphan to the human being twice a day. 13. The method of claim 1, comprising co-administering hydroxybupropion or bupropion with dextromethorphan to the human being once a day. 14. The method of claim 1, wherein, on the eighth day, the AUC0-12 of hydroxybupropion is at least about 3000 ng·hr/mL. 15. The method of claim 1, wherein, on the eighth day, the AUC0-12 of hydroxybupropion is at least about 7000 ng·hr/mL. 16. The method of claim 1, wherein the hydroxybupropion, bupropion, or dextromethorphan is deuterium modified. 17. The method of claim 16, wherein the dextromethorphan is deuterium modified.